Clinical trial
Oxaliplatin and Bortezomib in Treating Patients With Advanced Cancer
NCT00066625 · National Cancer Institute (NCI), NIH · Terminated
Key facts
| NCT number | NCT00066625 |
|---|---|
| Title | Oxaliplatin and Bortezomib in Treating Patients With Advanced Cancer |
| Official title | A Phase I and Pharmacokinetic Study of Oxaliplatin (Eloxatin™) in Combination With Bortezomib (PS-341, Velcade™) in Patients With Advanced Malignancy |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Drug, Other |
| Interventions | oxaliplatin, bortezomib, laboratory biomarker analysis, pharmacological study |
| Enrollment | 30 |
| Start date | Jul 1, 2003 |
| Primary completion | Apr 1, 2007 |
| First posted | Aug 7, 2003 |
| Last update posted | Feb 1, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: